Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Myelomonocytic Leukemia (CMML): early-phase trial registry
4 of 7 indexed Chronic Myelomonocytic Leukemia (CMML) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Chronic Myelomonocytic Leukemia (CMML): 7 US clinical trials tracked, 4 recruiting.
Chronic Myelomonocytic Leukemia (CMML) is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Crossbow Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition chronic-myelomonocytic-leukemia-cmml
OPEN 4 | RECR 57% | LATE 0 | EARLY 7 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
Chronic Myelomonocytic Leukemia (CMML) lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Myelomonocytic Leukemia (CMML) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Myelomonocytic Leukemia (CMML) is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Myelomonocytic Leukemia (CMML) trials is spread across many organizations.
Crossbow Therapeutics accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Myelomonocytic Leukemia (CMML) enrolment sits around 102 participants.
Median target enrolment is 102 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
Chronic Myelomonocytic Leukemia (CMML) research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT06859424
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Solu Therapeutics
NCT06950034
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Crossbow Therapeutics
NCT06994676
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
M.D. Anderson Cancer Center
NCT07128381
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT04603001
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Jacqueline Garcia, MD
NCT03613532
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
University of Utah
NCT04409639
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Myelomonocytic Leukemia (CMML) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Myelomonocytic Leukemia (CMML) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Myelomonocytic Leukemia (CMML) page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Chronic Myelomonocytic Leukemia (CMML) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Crossbow Therapeutics sponsors the most Chronic Myelomonocytic Leukemia (CMML) trials on record, review their full trial history before evaluating a specific study. See Crossbow Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Myelomonocytic Leukemia (CMML) condition card totals 7 registered trials; most-linked intervention Azacitidine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.